Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 12/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13927747 | 0.92 | MAPK1 (0.38) | SCN9ALMNACAPN1CTSBMAPK1 | |
| SCHEMBL6426817 | 0.92 | MAPK1 (0.34) | SCN9ALMNACAPN1CTSBMAPK1 | |
| SCHEMBL6426733 | 0.90 | LMNA (0.32) | LMNACAPN1CTSBMAPK1JAK2 | |
| SCHEMBL5034298 | 0.88 | SCN9A (0.36) | SCN9ALMNACAPN1CTSBMAPK1 | |
| SCHEMBL4139333 | 0.85 | TRPA1 (0.32) | JAK2 | |
| SCHEMBL4139328 | 0.85 | TRPA1 (0.32) | JAK2 | |
| SCHEMBL5032386 | 0.85 | LMNA (0.35) | SCN9ALMNACAPN1CTSBMAPK1 | |
| SCHEMBL6428642 | 0.85 | DCAF1 (0.40) | MAPK1 | |
| SCHEMBL4153253 | 0.84 | LMNA (0.38) | LMNAHPGD | |
| SCHEMBL4153260 | 0.84 | LMNA (0.38) | LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | SCN9A 2678/4885LMNA 3498/4885CAPN1 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.